Wednesday 27 November 2013

Durata Therapeutics Announces FDA’s Acceptance for Priority Review of NDA for Dalvance (dalbavancin hydrochloride) « New Drug Approvals

Durata Therapeutics Announces FDA’s Acceptance for Priority Review of NDA for Dalvance (dalbavancin hydrochloride) « New Drug Approvals:

'via Blog this'

No comments:

Post a Comment